UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) | Delaware | 001-39318 | 46-3973463 | | --- | --- | --- | | (State or Other Jurisdiction | (Commission File Number) | (IRS Employer | | of Incorporation) | | Identification No.) | | 1920 McKinney Avenue, 7th Floor Dallas, Texas | | 75201 | (Address of Principal Executive ...

Fourth quarter 2021 Operating & Financial Results Conference Call / Webinar March 10th, 2022 4:30 PM Eastern Time NASDAQ:LTRN TODAY'S SPEAKERS Panna Sharma Chief Executive Officer, Chief Scientific Officer Investor Relations President and Director Chief Financial Officer and Secretary David Margrave Dr. Kishor Bhatia Nicole Leber NASDAQ:LTRN 1 LTRN Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and ...

Lantern Pharma Inc. (NASDAQ:LTRN) Q4 2021 Earnings Conference Call March 10, 2022 4:30 PM ET Company Participants Nicole Leber - Investor Relations Panna Sharma - President and CEO David Margrave - Chief Financial Officer Kishor Bhatia - Chief Scientific Officer Conference Call Participants Michael King - H.C. Wainwright Kyle Bauser - Colliers Int’l. Securities Nicole Leber Good afternoon, everybody. And welcome to the Lantern Pharma Fourth Quarter and Fiscal Year 2021 Earnings Call. As a reminder, this cal ...

For the fiscal year ended December 31, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 19 ...

Call Start: 16:30 January 1, 0000 5:25 PM ET Lantern Pharma Inc. (NASDAQ:LTRN) Q3 2021 Earnings Conference Call November 1, 2021 16:30 ET Company Participants Nicole Leber - Finance & Administrative Coordinator Panna Sharma - President, Chief Executive Officer & Director David Margrave - Chief Financial Officer & Secretary Kishor Bhatia - Chief Scientific Officer & Scientific Consultant Conference Call Participants Nicole Leber We'll get started here. Good afternoon. And welcome to the Lantern Pharma's Thir ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (972) 277-1136 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Common Stock | | | Name of each excha ...

| --- | --- | --- | --- | |---------------------------------------------------------------------------------------------------------------------------------------|-------|-------|-------| | | | | | | Lantern Pharma | | | | | Company Overview September 13, 2021 | | | | | Leveraging A.I., machine learning & genomics to transform the cost, pace, and timeline of oncology drug discovery and development | | | | | Nasdaq: LTRN | | | | 1 LTRN FORWARD-LOOKING STATEMENTS This presentation contains forward-looking sta ...

Lantern Pharma Inc. (NASDAQ:LTRN) Q2 2021 Earnings Conference Call July 29, 2021 4:30 PM ET Company Participants Panna Sharma - President and CEO David Margrave - CFO Kishor Bhatia - CSO Conference Call Participants Kyle Bauser - Colliers Securities John Vandermosten - Zacks SCR Operator Good afternoon and welcome to Lantern Pharma’s Second Quarter 2021 Conference Call. As a reminder, this call is being recorded and all participants are in listen-only mode. We will open the call for questions-and-answers af ...

| --- | --- | |------------------------------------------------|-------| | | | | | | | Second Quarter 2021 | | | Operating & Financial Results Conference Call | | July 29, 2021 4:30 PM Eastern https://ir.lanternpharma.com/ LTRN FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other thin ...

FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) | Delaware | 001-39318 | 46-3973463 | | --- | --- | --- | | (State or Other Jurisdiction | (Commission | (IRS Emplo ...